


IN THE CLAIMS

Please amend the claims as follows. This listing of claims will replace all prior versions and listings of claims in the application.

1. (Currently Amended) A compound or a prodrug ester or a pharmaceutically acceptable salt or a stereoisomer thereof according to formula I



wherein

R₁ is selected from hydrogen (H), alkenyl or substituted alkenyl, CO₂R₄, CONR₄R₄' and CH₂OR₄;

R_2 and R_2' are each independently selected from hydrogen (H), alkyl, substituted alkyl, SR_3 , halo, NHR_4 , $NHCOR_4$, $NHCO_2R_4$, $NHCONR_4R_4'$ and $NHSO_2R_4$;

and at least one of R_2 and R_2' is H or alkyl;

R_3 in each functional group is independently selected from hydrogen (H), alkyl or substituted alkyl, CHF_2 , CF_3 and COR_4 ;

R_4 and R_4' in each functional group are each independently selected from hydrogen(H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, and aryl or substituted aryl;

R_5 and R_5' are each independently selected from hydrogen(H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl and arylalkyl or substituted arylalkyl, wherein at least one of R_5 and R_5' is hydrogen, or R_5 and R_5' taken together can form a double bond with oxygen (O), sulfur (S), NR_7 or CR_7R_7' ;

R_6 and R_6' are each independently at each occurrence selected from hydrogen(H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or

substituted cycloalkyl, and arylalkyl or substituted arylalkyl, wherein at least one of R_6 and R_6' is hydrogen, or R_6 and R_6' at each occurrence may be taken together to form a double bond with oxygen (O), sulfur (S), or CR_7R_7' ;

R_7 and R_7' in each functional group are each independently selected from hydrogen(H), OR_4 , alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, and aryl or substituted aryl;

G is an aryl group, wherein said group is mono- or polycyclic, and which is optionally substituted with one or more substituents selected from hydrogen, halo, CN, CF_3 , OR_4 , CO_2R_4 , NR_4R_4' , $CONR_4R_4'$, CH_2OR_4 , alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, and aryl or substituted aryl;

W is selected from (CR_6R_6') , $C(R_6)OR_3$, or $C(R_6)(NR_4R_4')$; and


n is 1;

with the following provisos:

(a) when R_5 and R_5' and/or R_6 and R_6' form a double bond with CR_7R_7' , then when either R_7 or R_7' is OR_4 , R_4 is not hydrogen;

(b) when

- (i) R_5 and R_5' are each H or taken together to be =O, =S or =CH₂,
- (ii) R_6 and R_6' on the imidazolidine portion of the bicyclic structure shown are selected from hydrogen(H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, and arylalkyl or substituted arylalkyl, wherein at least one of R_6 and R_6' on the imidazolidine portion of the bicyclic structure shown is hydrogen, or R_6 and R_6' on the imidazolidine portion of the bicyclic structure shown are taken together to form a double bond with oxygen (O) or sulfur (S),
- (iii) W is CR_6R_6' where R_6 and R_6' are each independently selected from H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl and arylalkyl or substituted arylalkyl, wherein at least one of R_6 and R_6' in W is H, and



(iv) G has the structure: wherein,

(v) —R₁₃ is selected from the group consisting of H, CN, NO₂, halo, heterocycle OR₁₄, CO₂R₁₅, CONHR₁₅, COR₁₅, S(O)_pR₁₅, SO₂NR₁₅R₁₅', NHCOR₁₅ and NHSO₂R₁₅, wherein p is an integer from 0 to 2,

(vi) R₁₄ in each functional group is independently selected from H, alkyl or substituted alkyl, CHF₂, CF₃ and COR₁₅,


(vii) R₁₅ and R₁₅' in each functional group are each independently selected from H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, heterocycloalkyl or substituted heterocycloalkyl arylalkyl or substituted arylalkyl, aryl or substituted aryl, and -CN,

and

(viii) A and B are each independently selected from H, halo, CN, NO₂, alkyl or substituted alkyl and OR₁₄,

then R₂ and R₂' are each independently selected from SR₃ and NHR₄.

2. (Previously Presented) The compound according to claim 1 wherein G is selected from:



wherein

R₈, R₉, R₁₀ and R₁₁ are each independently selected from hydrogen (H), NO₂, CN, CF₃, OR₄, CO₂R₄, NR₄R₄', CONR₄R₄', CH₂OR₄, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, and aryl or substituted aryl;

A to F is each independently selected from CR₉;

J, K, L, P and Q are each independently selected from CR₁₂R₁₂’;

R₁₂ and R₁₂’ in each functional group are each independently selected from a bond or R₁;





and

m is an integer of 0 or 1.

3. (Canceled).


4. (Original) The compound according to claim 2 wherein R₈ is -CN.

5. (Currently Amended) The compound according to claim 1 ~~selected from which is:~~



6. (Canceled).

7. (Currently Amended) The compound according to claim 22 1 selected from



8 to 11. (Canceled).

12. (Original) A pharmaceutical composition, comprising:


- (a) a compound according to claim 1; and
- (b) at least one pharmaceutically acceptable diluent or carrier.

13 to 22. (Canceled).


23. (Previously Presented) The compound according to claim 1 which is




24. (Previously Presented) The compound according to claim 1 which is




25. (Previously Presented) A pharmaceutical composition according to claim 12, wherein the compound according to claim 1 is




26. (Previously Presented) A pharmaceutical composition according to claim 12, wherein the compound according to claim 1 is




27. (New) The compound according to claim 1 which is




28. (New) The compound according to claim 1 which is




29. (New) The compound according to claim 1 which is




30. (New) The compound according to claim 1 which is




31. (New) The compound according to claim 1 which is




32. (New) The compound according to claim 1 which is




33. (New) The compound according to claim 1 which is




34. (New) The compound according to claim 1 which is




35. (New) The compound according to claim 1 which is



36. (New) The compound according to claim 1 which is



37. (New) The compound according to claim 1 which is



38. (New) The compound according to claim 1 which is

